[7]
Medline Plus. Degenerative nerve diseases. Health Topics, 2021, 2022
[11]
Facts and figures. Alzheimer's and Dementia, , 2021, 2022(17(3)), 327-406.
[13]
Foundation, P.s. Understanding Parkinson's. Parkinson's foundation, 2022, 2022
[14]
Yohrling, G.; Raimundo, K.; Crowell, V.; Lovecky, D.; Vetter, L.; Seeberger, L. Prevalence of huntington’s disease in the US (954); AAN Enterprises, 2020.
[25]
Sharma, H.; Chawla, P.A.; Bhatia, R. 1, 3, 5-Pyrazoline derivatives in cns disorders: synthesis, biological evaluation and structural insights through molecular docking.
CNS & Neurological Disorders- Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2020, 19(6), 448-465.
[30]
Motor Neuron Disease. Disorders, 2019, 2022
[116]
Lema Abdullahi, A.; Lema, A.; Jibrin, K.; Nuraddeen, W.; Alexander, E. Ameliorative role of nutraceutical quercetin and its derivatives against cognitive impairment process induced by lead exposure in Drosophila melanogaster (Fruit Fly). Iraqi J. Pharm Sci., 2021, 30(2), 135-142.
[153]
Patel, K.; Patel, D.K. The Beneficial Role of Rutin, A naturally occurring flavonoid in health promotion and disease prevention: A systematic review and update. In: Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases, 2nd ed; Academic Press, 2019; pp. 457-479.
[160]
Neta, F.; Da Costa, I.; Lima, F.; Fernandes, L.; Cavalcanti, J.; Freire, M.; Lucena, E.D.S.; Do Rêgo, A.M.; De Azevedo, E.; Guzen, F. Effects of Mucuna pruriens (L.) supplementation on experimental models of Parkinson’s disease: A systematic review. Pharmacogn. Rev., 2018, 12(23), 78-84.
[170]
Siahaan, E.A.; Pangestuti, R.; Pratama, I.S.; Putra, Y.; Kim, S-K. Beneficial effects of astaxanthin in cosmeceuticals with focus on emerging market trends. In: Global Perspectives on Astaxanthin; Ravishankar, G.A.; Ranga, R.A., Eds.; Academic Press, 2021; pp. 557-568.
[174]
Chen, C-C.; Lee, H-C.; Chang, J-H.; Chen, S-S.; Li, T-C.; Tsai, C-H.; Cho, D-Y.; Hsieh, C-L. Chinese herb Astragalus membranaceus enhances recovery of hemorrhagic stroke: double-blind, placebo-controlled, randomized study. Evid-Based Compl Alter Med, 2012, 2012, 708452.
[179]
Sánchez-Illana, Á.; Piñeiro-Ramos, J.D.; Ramos-Garcia, V.; Ten-Doménech, I.; Vento, M.; Kuligowski, J. Chapter Three - Oxidative stress biomarkers in the preterm infant. Adv. Clin. Chem; Makowski, G.S., Ed.; Elsevier, 2021, Vol. 102, pp. 127-189.
[197]
Wu, W.; Han, H.; Liu, J.; Tang, M.; Wu, X.; Cao, X.; Zhao, T.; Lu, Y.; Niu, T.; Chen, J. Fucoxanthin prevents 6-OHDA-induced neurotoxicity by targeting Keap1. Oxid. Med. Cell. Long.,, 2021, 2021
[244]
Addington, O.C.; Newman, R.A. Method of treating neurological conditions with oleandrin. US Patent US 9,877,979, 2018.
[245]
Mazed, M.A.; Mazed, S. Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance. US Patent US 8017147 B2, 2011.
[246]
Gennari, G.; Panfilo, S. Pharmaceutical compositions containing phosphatidylserine and curcumin. US Patent US 9381204 B2, 2016.
[247]
Tan, J.; Luo, D.; Shytle, R.D. Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism. US Patent US 8778894 B2, 2014.
[248]
Crowley, K.L. Buccal and sublingual cannabinoid formulations and method of making the same. EP Patent EP 3160451 B1 2021.
[249]
Rupasinghe, H.P.; Robertson, G.S. Phenolic compositions derived from apple skin and uses thereof. US Patent US 9511107 B2 2016.
[250]
Soman, G.S.; Phadke, S.G. Herbal composition for reducing ADD/ ADHD and method thereof. US Patent US 8394429 B2, 2013.
[251]
Baraona, R.M.; Sepúlveda, L.Q.; Saavedra, I.S.; Salas, R.S.; Salas, V.S. Nutraceutical composition that comprises extract of andean shilajit, for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral aging. US Patent US 8784804 B2, 2014.
[252]
Guy, G.; Platt, B. Cannabinoid-containing plant extracts as neuroprotective agents. US Patent US 8673368 B2 2014.
[253]
Choi, P.; Castillo, G.; Nguyen, B.; Snow, A.; Cummings, J. Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders. CA Patent CA 2440293 C, 2012.